Adaptive Biotechnologies CorporationADPTNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-1.93%
↓ 152% below average
Average (30q)
3.74%
Historical baseline
Range
High:32.40%
Low:-16.17%
Volatility
1298.6%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -1.93% |
| Q2 2025 | -0.29% |
| Q1 2025 | 4.36% |
| Q4 2024 | -4.02% |
| Q3 2024 | -4.69% |
| Q2 2024 | -16.17% |
| Q1 2024 | 5.21% |
| Q4 2023 | 0.75% |
| Q3 2023 | -11.49% |
| Q2 2023 | -1.12% |
| Q1 2023 | 4.42% |
| Q4 2022 | -12.44% |
| Q3 2022 | -3.72% |
| Q2 2022 | -2.12% |
| Q1 2022 | 9.05% |
| Q4 2021 | -3.81% |
| Q3 2021 | -4.57% |
| Q2 2021 | 11.93% |
| Q1 2021 | -5.75% |
| Q4 2020 | 18.20% |
| Q3 2020 | 16.63% |
| Q2 2020 | 8.59% |
| Q1 2020 | 12.96% |
| Q4 2019 | 3.33% |
| Q3 2019 | 24.08% |
| Q2 2019 | 32.40% |
| Q1 2019 | 12.79% |
| Q4 2018 | 13.12% |
| Q3 2018 | 3.50% |
| Q2 2018 | 6.74% |
| Q1 2018 | 0.00% |